Communiqués Gilead Sciences, Inc.

Actions

GILD

US3755581036

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/06/2026			Après clôture 02:00:00
125,45 ^USD	-1,40%		120,61	-3,86%

16/06	Gilead Sciences : un dirigeant cède pour 376 200 $ d'actions, selon un document de la SEC	MT
16/06	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime

Communiqués

16/06	U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	AQ
15/06	U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	BU
12/06	Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief	BU
11/06	National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership	BU
09/06	UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir	AQ
05/06	Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa	BU
02/06	Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)	BU
27/05	Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)	BU
22/05	FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)	BU
22/05	Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors	BU
21/05	New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology	BU
21/05	Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio	BU
21/05	Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease	BU
15/05	Gilead Prices $3 Billion of Senior Unsecured Notes	BU
13/05	Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026	BU
08/05	Gilead Sciences : First Quarter 2026 Resource Book	PU
08/05	Gilead Sciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
08/05	Gilead Sciences : First Quarter 2026 Prepared Remarks	PU
08/05	Gilead Sciences : First Quarter 2026 Summary of Remarks	PU
07/05	Gilead Sciences : First Quarter 2026 Supplementary Information	PU
07/05	Gilead: Q1 Earnings Snapshot	AQ
07/05	Gilead Sciences Announces First Quarter Financial Results	BU
01/05	Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences	BU
29/04	U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir	BU
28/04	Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel	BU